Henan Tianfu Chemical Co., Ltd.
China
Product Name: WARFARIN SODIUM
Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
Purity: 99.0%
Stocking Period: Inquiry
Contact: Anson
Email: info@tianfuchem.com

129-06-6

129-06-6 structure

Name: Warfarin sodium
Chemical Name: warfarin-sodium
CAS Number: 129-06-6
Molecular Formula: C₁₉H₁₅NaO₄
Molecular Weight: 330.310
Catalog: API Blood system medication Anticoagulant and antiplatelet drugs
Create Date: 2018-07-01 07:43:12
Modify Date: 2026-08-01 09:18:46
Warfarin sodium (WARF-42 sodium; Athrombine-K sodium) is a potent anticoagulant agent and a vitamin K1 recycling antagonist to deplete active vitamin K1. Warfarin sodium decreases blood coagulation and prevents blood clot formation by inhibiting vitamin K epoxide reductase[1][2].

Name	warfarin-sodium
Synonyms	sodiumwfin UNII:6153CWM0CL 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2h-1-benzopyran-2-onsodiumsalt 3-(alpha-Acetonylbenzyl)-4-hydroxycouMin sodiuM salt >= WARFARIN SODIUM, EP STANDARD 3-(alpha-Acetonylbenzyl)-4-hydroxycoumin Sodiuim Salt 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one(C19H15O4) zoocouminsodiumsalt 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt (contains Isopropyl Alcohol) 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-onesodiumsalt3-(a-Acetonylbenzyl)-4-hydroxycouminsodiumsalt Wfin Sodium (contains Isopropyl Alcohol) zoocoumarin-sodium WFIN SODIUM SALT warfilone Coumin, 3-(a-acetonylbenzyl)-4-hydroxy-, sodium salt 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one sodium salt vfine coumafenesodium WFINSODIUM,CRYSTALLINE 3-(A-ACETONYLBENZYL)-4-HYDROXYCOUMIN SODIUM mevan Wfin sodiuM( Isopropanol) wcoumin WARFARIN SODIUM, (CONTAINS ISOPROPYL ALCOHOL) 3-(ALPHA-ACETONYLBENZYL)-4-HYDROXYCOUMARIN SODIUM CLATHRATE waran coumadin Warfarinsodium 3-(α-Acetonylbenzyl)-4-hydroxycoumin, sodium salt ratsulsoluble SODIUM3-(ALPHA-ACETONYLBENZYL)-4-HYDROXYCOUMIN sodium 2-oxo-3-(3-oxo-1-phenylbutyl)-1-benzopyran-4-olate VITAMIN K2 4-Sodiooxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one coumadinsodium 3-(A-ACETONYLBENZYL)-4-HYDROXYCOUMARIN SODIUM SALT 3-(α-Acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt (contains Isopropyl Alcohol) 3-(A-ACETONYLBENZYL)-4-HYDROXYCOUMIN, SODIUM CLAT 3-(ALPHA-ACETONYLBENZYL)-4-HYDROXYCOUMIN SODIUM WFIN SODIUM BP WFIN, SODIUM CLATHRATE 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one sodium salt panwarfin EINECS 204-929-4 3-(Alpha-Acetonylbenzyl)-4-Hydroxycoumarin Sodiuim Salt 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, sodium salt (1:1) 3-(α-ACETONYLBENZYL)-4-HYDROXYCOUMARIN SODIUM SALT 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, sodium salt 3-(A-ACETONYLBENZYL)-4-HYDROXYCOUMARIN 3-(ALPHA-ACETONYLBENZYL)-4-HYDROXYCOUMIN SODIUM CLATHRATE 3-(ALPHA-ACETONYLBENZYL)-4-HYDROXYCOUMIN panwfin prothromadin sodiumcoumadin 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one sodium salt sodium salt Wfin sodium, >= athrombin Wfin sodium clathrate CRS WARFARIN SODIUMLINE Wfin sodium //BP acetonylbenzyl SODIUM 4-OXO-3-(3-OXO-1-PHENYL-BUTYL)-CHROMEN-2-OLATE 2-hydroxy-3-[(1S)-3-oxo-1-phenylbutyl]-4H-chroMen-4-one WFIN SODIUM SALT CLATHRATE ((3-(alpha-acetonylbenzyl)-2-oxo-2h-1-benzopyran-4-yl)oxy)-sodiu 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumin sodium salt Wfin Sodium Amorphous ( Under Development ) Sodium 2-oxo-3-(3-oxo-1-phenylbutyl)-2H-chromen-4-olate wan WFIN SODIUM WFIN SODIUM CRYSTALLINE CLATHRATE 3-(alpha-acetonylbenzyl)-4-hydroxy-coumisodiumsalt warfarin sodium salt WFIN SODIUM 26 wfin,sodiumderiv tintorane MFCD00083223 3-(α-Acetonylbenzyl)-4-hydroxycoumin sodium salt 3-(alpha-Acetonylbenzyl)-4-hydroxycoumin Sodiuim Salt 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumin Sodium Salt rac-sodium 2-oxo-3-[(1R)-3-oxo-1-phenylbutyl]-2H-1-benzopyran-4-olate Warfarin SodiuM (contains Isopropyl Alcohol) wfilone varfine 3-(A-ACETONYLBENZYL)-4-HYDROXYCOUMARIN SODIUM warcoumin sodium 2-oxo-3-[(RS)-3-oxo-1-phenylbutyl]-2H-chromen-4-olate 3-(ALPHA-ACETONYLBENZYL)-4-HYDROXYCOUMIN SODIUM SALT marevan

Description	Warfarin sodium (WARF-42 sodium; Athrombine-K sodium) is a potent anticoagulant agent and a vitamin K1 recycling antagonist to deplete active vitamin K1. Warfarin sodium decreases blood coagulation and prevents blood clot formation by inhibiting vitamin K epoxide reductase[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others
Target	IC50: vitamin K1 recycling[1]
References	[1]. Ansell, J., et al., Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008. 133(6 Suppl): p. 160S-198S. [2]. http://en.wikipedia.org/wiki/Warfarin

Density	1.307g/cm3
Boiling Point	515.2ºC at 760mmHg
Molecular Formula	C₁₉H₁₅NaO₄
Molecular Weight	330.310
Flash Point	188.8ºC
Exact Mass	330.086792
PSA	70.34000
LogP	4.04780

CHEMICAL IDENTIFICATION

RTECS NUMBER :: GN4725000

CHEMICAL NAME :: Coumarin, 3-(alpha-acetonylbenzyl)-4-hydroxy-, sodium salt

CAS REGISTRY NUMBER :: 129-06-6

LAST UPDATED :: 199706

DATA ITEMS CITED :: 38

MOLECULAR FORMULA :: C19-H15-O4.Na

MOLECULAR WEIGHT :: 330.33

WISWESSER LINE NOTATION :: T66 BOVJ DYR&1V1 EQ &-NA-

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 300 ug/kg/2D

TOXIC EFFECTS :: Skin and Appendages - dermatitis, other (after systemic exposure)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - child

DOSE/DURATION :: 4 mg/kg

TOXIC EFFECTS :: Blood - changes in cell count (unspecified)

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 8700 ug/kg

TOXIC EFFECTS :: Blood - hemorrhage

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 25 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 374 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 160 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Blood - hemorrhage Skin and Appendages - hair

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 800 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 100 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Blood - hemorrhage Skin and Appendages - hair

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 182 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 543 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Bird - chicken

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Blood - hemorrhage Skin and Appendages - hair

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 4280 ug/kg/11D-C

TOXIC EFFECTS :: Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 20 mg/kg/4D-I

TOXIC EFFECTS :: Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 9300 ug/kg/31D-C

TOXIC EFFECTS :: Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Bird - chicken

DOSE/DURATION :: 1484 mg/kg/15W-C

TOXIC EFFECTS :: Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 160 mg/kg

SEX/DURATION :: female 1-17 week(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 21700 ug/kg

SEX/DURATION :: female 1-31 week(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - physical

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 26 mg/kg

SEX/DURATION :: female 1-38 week(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - skin and skin appendages Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 26 mg/kg

SEX/DURATION :: female 1-38 week(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - gastrointestinal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 37 mg/kg

SEX/DURATION :: female 1-35 week(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 12 mg/kg

SEX/DURATION :: female 1-35 week(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 12 mg/kg

SEX/DURATION :: female 1-35 week(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - Apgar score (human only)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 2450 mg/kg

SEX/DURATION :: female 7-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 2450 mg/kg

SEX/DURATION :: female 7-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - biochemical and metabolic

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 1 mg/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 4 mg/kg

SEX/DURATION :: female 11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 18 mg/kg

SEX/DURATION :: female 3-11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 18 mg/kg

SEX/DURATION :: female 3-11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - other measures of fertility Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 54 mg/kg

SEX/DURATION :: female 2-28 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility Reproductive - Effects on Newborn - stillbirth

MUTATION DATA

TYPE OF TEST :: Mutation test systems - not otherwise specified

TEST SYSTEM :: Rodent - mouse Leukocyte

DOSE/DURATION :: 100 nmol/L

REFERENCE :: ONCOBS Oncology. (S. Karger AG, Postfach CH-4009 Basel, Switzerland) V.21- 1967- Volume(issue)/page/year: 28,232,1973 *** REVIEWS *** TOXICOLOGY REVIEW NYSJAM New York State Journal of Medicine. (Medical Soc. of the State of New York, POB 5405, Lake Success, NY 11042) V.1- 1901- Volume(issue)/page/year: 64,493,1964 TOXICOLOGY REVIEW JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1883- Volume(issue)/page/year: 203,223,1968 *** U.S. STANDARDS AND REGULATIONS *** EPA FIFRA 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION FEREAC Federal Register. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) V.1- 1936- Volume(issue)/page/year: 54,7740,1989 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5375 No. of Facilities: 55 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 786 (estimated) No. of Female Employees: 522 (estimated)

Symbol	GHS06, GHS08
Signal Word	Danger
Hazard Statements	H300-H360
Precautionary Statements	Missing Phrase - N15.00950417-P201-P280-P308 + P313
Hazard Codes	T+:Verytoxic;
Risk Phrases	R61;R28
Safety Phrases	S53-S36/37/39-S45
RIDADR	UN 1544 6.1/PG 2
WGK Germany	1
RTECS	GN4725000
Packaging Group	II
Hazard Class	6.1(a)
HS Code	2932209090

81-81-2

129-06-6

Literature: WO2008/44246 A2, ; Page/Page column 6-8 ;

Precursor 1
81-81-2
DownStream 1
24579-14-4

HS Code	2932209090
Summary	2932209090. other lactones. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1214369-14-8	200273-58-1
1214369-17-1	1214366-52-5
1056418-53-1	1214383-60-4
1214344-29-2	1214391-33-9
1214382-23-6	1214361-54-2